12 Month Price Forecast For HRMY
Distance to HRMY Price Forecasts
HRMY Price Momentum
🤔 Considering Harmony Biosciences (HRMY)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 8:14 AM UTC
HRMY Analyst Ratings & Price Targets
Based on our analysis of 14 Wall Street analysts, HRMY has a consensus that is bullish. The median price target is $54.00, with forecasts ranging from $32.00 to $75.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 1 Sell ratings.
With HRMY currently trading at $38.66, the median price forecast suggests a 39.7% upside. The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 94.0% upside, while at provides the most conservative target, suggesting a -17.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HRMY Analyst Consensus
HRMY Price Target Range
Latest HRMY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HRMY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 16, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Jan 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Oct 30, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Maintains | $58.00 |
| Oct 30, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Oct 30, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $59.00 |
| Oct 29, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Oct 10, 2024 | Raymond James | Danielle Brill | Outperform | Reinstates | $40.00 |
| Oct 10, 2024 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $52.00 |
| Oct 2, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Sep 24, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Sep 12, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Sep 10, 2024 | UBS | Ashwani Verma | Buy | Initiates | $56.00 |
| Aug 8, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Aug 6, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Jun 25, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Jun 24, 2024 | Needham | Ami Fadia | Buy | Reiterates | $52.00 |
| Jun 21, 2024 | Citigroup | David Hoang | Buy | Initiates | $48.00 |
| May 1, 2024 | Needham | Ami Fadia | Buy | Maintains | $52.00 |
| Apr 30, 2024 | Needham | Ami Fadia | Buy | Reiterates | $50.00 |
Stocks Similar to Harmony Biosciences Holdings, Inc.
The following stocks are similar to Harmony Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Harmony Biosciences Holdings, Inc. (HRMY) Financial Data
Harmony Biosciences Holdings, Inc. has a market capitalization of $2.23B with a P/E ratio of 18.5x. The company generates $681.88M in trailing twelve-month revenue with a 18.0% profit margin.
Revenue growth is +16.1% quarter-over-quarter, while maintaining an operating margin of +33.2% and return on equity of +22.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Harmony Biosciences Holdings, Inc. (HRMY) Company Overview
About Harmony Biosciences Holdings, Inc.
Develops therapies for neurological diseases.
Harmony Biosciences Holdings, Inc. generates revenue through the development and commercialization of pharmaceutical therapies, particularly focusing on rare neurological conditions. Its primary product, WAKIX, is designed to treat excessive daytime sleepiness in narcolepsy patients, providing a unique mechanism of action that differentiates it from competitors.
Founded in 2017 and based in Plymouth Meeting, Pennsylvania, the company has undergone rebranding, previously operating as Harmony Biosciences II, Inc. Its ongoing commitment to addressing unmet medical needs in the neurological space positions it strategically in the pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
246
CEO
Dr. Jeffrey M. Dayno M.D.
Country
United States
IPO Year
2020
Website
www.harmonybiosciences.comHarmony Biosciences Holdings, Inc. (HRMY) Latest News & Analysis
Zacks utilizes its Rank system, focusing on earnings estimates and revisions, while also monitoring value, growth, and momentum trends to identify strong stock picks.
The Zacks Rank system highlights stocks with favorable earnings estimates, influencing investment decisions based on growth and momentum trends, potentially leading to stronger returns.
Analysts' price targets for Harmony Biosciences (HRMY) suggest a 39.5% upside, supported by a consensus increase in earnings estimates.
Analysts' bullish price targets suggest potential for significant gains in Harmony Biosciences, indicating positive market sentiment and potential earnings growth.
Harmony Biosciences (HRMY) shares are showing upward momentum, supported by positive earnings estimate revisions, suggesting potential for further gains.
Solid earnings estimate revisions for Harmony Biosciences signal potential growth, which can drive share prices higher, attracting investor interest and potentially increasing market value.
Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN) are notable stocks in the Medical - Biomedical and Genetics sector, attracting investor interest for potential undervaluation.
The comparison of Harmony Biosciences and Repligen highlights potential investment opportunities in an undervalued segment, influencing stock selection strategies in the biomedical sector.
Harmony Biosciences (Nasdaq: HRMY) reported preliminary Q4 2024 net revenues of $201 million and full-year revenues of $714 million, with significant milestones expected in 2025.
Strong revenue projections and a catalyst-rich outlook for 2025 signal potential growth and value creation for Harmony Biosciences, influencing investor sentiment and stock performance.
At JPM, biotech stocks had mixed results; BridgeBio, ARS Pharma, and Harmony Bio delivered strong preliminary reports, highlighting positive investor interest.
Strong preliminary reports from BridgeBio, ARS Pharma, and Harmony at JPM indicate potential growth and investor interest in biotech, impacting stock valuations and market sentiment.
Frequently Asked Questions About HRMY Stock
What is Harmony Biosciences Holdings, Inc.'s (HRMY) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Harmony Biosciences Holdings, Inc. (HRMY) has a median price target of $54.00. The highest price target is $75.00 and the lowest is $32.00.
Is HRMY stock a good investment in 2025?
According to current analyst ratings, HRMY has 7 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $38.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for HRMY stock?
Wall Street analysts predict HRMY stock could reach $54.00 in the next 12 months. This represents a 39.7% increase from the current price of $38.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Harmony Biosciences Holdings, Inc.'s business model?
Harmony Biosciences Holdings, Inc. generates revenue through the development and commercialization of pharmaceutical therapies, particularly focusing on rare neurological conditions. Its primary product, WAKIX, is designed to treat excessive daytime sleepiness in narcolepsy patients, providing a unique mechanism of action that differentiates it from competitors.
What is the highest forecasted price for HRMY Harmony Biosciences Holdings, Inc.?
The highest price target for HRMY is $75.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 94.0% increase from the current price of $38.66.
What is the lowest forecasted price for HRMY Harmony Biosciences Holdings, Inc.?
The lowest price target for HRMY is $32.00 from at , which represents a -17.2% decrease from the current price of $38.66.
What is the overall HRMY consensus from analysts for Harmony Biosciences Holdings, Inc.?
The overall analyst consensus for HRMY is bullish. Out of 14 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $54.00.
How accurate are HRMY stock price projections?
Stock price projections, including those for Harmony Biosciences Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
